STOCK TITAN

Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.

Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:

  • Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
  • Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
  • Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.

In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.

Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.

Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.

Rhea-AI Summary

Teva Pharmaceuticals presented new analyses from the COBRA study at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The study, which included data from 99 mothers with multiple sclerosis treated with COPAXONE® (glatiramer acetate) during pregnancy and breastfeeding, found no safety concerns for infants. Specifically, there were no adverse effects on hospitalizations, antibiotic treatments, developmental delays, or growth during the first 18 months. This research addresses significant medical needs concerning treatment safety for women with MS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
none
-
Rhea-AI Summary

U.S. federal judge dismisses AbbVie's trade secret lawsuit against Alvotech, affirming its path to market a biosimilar to Humira. This ruling, delivered on October 6, 2021, supports Alvotech's goal to provide affordable medications. Alvotech has submitted a Biologics License Application for its candidate, AVT02, which aims for FDA interchangeability designation with Humira. Teva Pharmaceuticals is Alvotech's exclusive U.S. commercialization partner for AVT02, enhancing market opportunities in a space valued at US$20 billion globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
-
Rhea-AI Summary

Teva Pharmaceuticals has released research indicating a growing demand among patients for awareness of drug manufacturing origins in Europe. The study reveals that 71% of patients want to know where their medicines are produced, citing concerns over the concentration of manufacturing overseas. 84% of those surveyed support government investments in local pharmaceutical production. The pandemic has highlighted vulnerabilities in global supply chains, necessitating a rebalancing in the pharmaceutical value chain. Teva asserts its commitment to invest close to 1 billion euros in European manufacturing facilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. will announce its third-quarter financial results on October 27, 2021, at 7:00 a.m. ET. A conference call will follow at 8:00 a.m. ET, available via phone or a live webcast on Teva's website. Interested parties can join by dialing specific numbers based on their location. Teva is a leader in generic and specialty medicines, with over 3,500 products serving approximately 200 million patients daily.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
-
Rhea-AI Summary

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced the presentation of 8 studies on AJOVY (fremanezumab) at the 25th World Congress of Neurology (WCN), occurring virtually from October 3-7, 2021. Highlights include pooled analyses on efficacy, safety, and quality of life improvements among diverse patient groups. The company will host an online symposium on October 3, focusing on healthcare disparities in migraine treatment. The studies aim to enhance understanding of migraine and promote inclusivity in clinical research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
conferences
-
Rhea-AI Summary

Teva Pharmaceuticals has launched a national campaign called Inhaler Tales aimed at addressing improper inhaler use among asthma and COPD patients. An animated inhaler, voiced by actress Sarah Michelle Gellar, is central to the campaign, which raises awareness about the impact of inhaler misuse on disease control. A survey reveals that 40% of patients feel their respiratory conditions disrupt their lives, yet many are confident they use their inhalers correctly. However, only 45% adhere to their maintenance inhaler usage as prescribed, indicating a significant gap in effective disease management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
Rhea-AI Summary

Teva Pharmaceuticals has reached a settlement with the Attorney General of Louisiana concerning opioid-related claims. The agreement, contingent upon state confirmation by November 2, 2021, includes a payment of $15 million over 18 years and the donation of $3 million worth of lifesaving medicines. Teva is also pursuing a national settlement and continues defending itself in ongoing litigation in states like New York and California. The company views this settlement as a significant step toward aiding those affected by opioid addiction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
none
-
Rhea-AI Summary

Alvotech announced the FDA has deferred action on the application for AVT02, a proposed biosimilar to Humira, pending necessary facility assessments. The FDA can defer without identifying deficiencies when inspections cannot be completed due to factors such as travel restrictions. Alvotech collaborates with the FDA for safe coordination of inspections. They are the only company that has conducted a switching study supporting interchangeability for Humira's high-concentration biosimilar. Teva Pharmaceuticals is the exclusive partner for AVT02's commercialization in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary

Alvotech announced positive top-line results from a randomized study evaluating the bioequivalence of its biosimilar AVT02 (adalimumab) and Humira, demonstrating no significant differences in efficacy, safety, or immunogenicity. This study, aimed at supporting FDA approval as an interchangeable product, involved 568 patients across Europe. Alvotech is the first to submit a high-concentration biosimilar for Humira and has partnered with Teva Pharmaceuticals for U.S. commercialization. These results mark a significant milestone towards providing affordable treatment options for chronic conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
none
Rhea-AI Summary

Teva Pharmaceuticals announced positive results from a network meta-analysis evaluating the effectiveness of AJOVY (fremanezumab), atogepant, and rimegepant in preventing episodic migraine. This analysis showed AJOVY's superiority in reducing monthly migraine days compared to both atogepant and rimegepant. The findings were shared during the International Headache Society Congress on September 8-12, 2021. AJOVY stands out as the only long-acting anti-CGRP subcutaneous injection approved for migraine prevention. The study reinforces the value of AJOVY in improving patient outcomes with significant migraine burdens.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none

FAQ

What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is $22.09 as of December 20, 2024.

What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?

The market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA) is approximately 24.7B.

What does Teva Pharmaceutical Industries Limited specialize in?

Teva specializes in generic drugs, active pharmaceutical ingredients, and proprietary pharmaceuticals.

Where is Teva headquartered?

Teva is headquartered in Tel Aviv, Israel.

What are some of Teva's key products?

Key products include Copaxone, Ajovy, Austedo, Qvar, ProAir, Truxima, Herzuma, and Bendeka/Treanda.

In which regions does Teva operate?

Teva operates in North America, Europe, Japan, Russia, and Israel.

How much of Teva's sales come from North America?

Approximately 50% of Teva's sales come from North America.

What therapeutic areas does Teva focus on?

Teva focuses on central nervous system, respiratory, and oncology therapeutic areas.

What is Anda?

Anda is a U.S.-based distributor of generic and specialty drugs owned by Teva.

Does Teva offer contract manufacturing services?

Yes, Teva offers contract manufacturing services.

What role does Teva play in the U.S. generic prescription market?

Teva accounts for a high-single-digit percentage of the total number of generic prescriptions in the U.S.

What recent advancements has Teva made?

Teva has made advancements in biosimilars and innovative treatments across its therapeutic areas.

Teva Pharmaceutical Industries Limited American Depositary Shares

NYSE:TEVA

TEVA Rankings

TEVA Stock Data

24.72B
1.13B
0%
57.83%
1.87%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
TEL AVIV